• News


Home>NEWS & MEDIA>News

Daewoong Pharmaceutical Co. Ltd. enters the biggest medicine market of U.S.A
Day : 2010-01-19


- 3rd to establish a global research facility,
  after India and Japan

- Researchers headed to Maryland after establishing
  a corporation in 2009

Daewoong Pharmaceutical Co., Ltd. (CEO Lee Jong-Wook) has announced its establishment of corporation in Maryland and its entering of the United States for the acceleration of the development of a new drug. The establishment of a corporation in the United States is the first of the top 10 Korean pharmaceutical companies. Daewoong Pharmaceutical Co., Ltd., to speed things up with the launching of their research facilities, sent their researchers to Maryland, USA, and stated on the 18th that they will push for product development and C&D activities.


Daewoong’s establishment of a corporation is a result of Daewoong’s constant good relations with other companies in USA in efforts to expand its reach to the American continent. Through this they achieved true global R&D research infrastructure and set the stage for them to become an international pharmaceutical company.


Daewoong Pharmaceutical Co., Ltd. will initially start their sales with injection (antibiotics and contrast Medium), according to their agendas, expand their market to new oral medicines by 2015. Through this method, they hope to expand their market in the United States, not to mention the development and exporting of new medicine they hope to develop.


Daewoong, so far, has put their efforts into building a research facility in India and China in order to gain international confidence in the market, and also work hard to acquire their license, raw material sourcing, co-research, and the acquiring of outstanding workforce.


Daewoong Pharmaceutical Co., Ltd., hopes to gain the synergy of their new research facilities through their expansion to the United States, and to further their development of a global network.


Prev Daewoong signed contract for sale of ‘Epliga’, an incrementally modified drug against epilepsy
Next URSA hits 0.1 million boxes in China only two months after launched